NRIX
NRIX clinical trials: Nurix Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Nurix Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
NRIX on the catalyst calendar · NRIX registry changes
- Primary completion May 2033Sponsor estimatePhase 1/Phase 2NCT07520006Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesNurix Therapeutics, Inc. · B-cell LymphomaRecruitingNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2028Sponsor estimatePhase 2NCT07221500A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor...Nurix Therapeutics, Inc. · Chronic Lymphocytic Leukemia (CLL)RecruitingNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2029Sponsor estimatePhase 3NCT07516093Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLNurix Therapeutics, Inc. · B-cell LymphomaRecruitingNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 1, 2026ActualPhase 1NCT06717269A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy...Nurix Therapeutics, Inc. · Healthy VolunteerCompletedNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1NCT05131022A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNurix Therapeutics, Inc. · Chronic Lymphocytic Leukemia (CLL)RecruitingNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2026Sponsor estimatePhase 1NCT04830137A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesNurix Therapeutics, Inc. · Chronic Lymphocytic Leukemia (CLL)RecruitingNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2026Sponsor estimatePhase 1NCT05107674A Study of NX-1607 in Adults With Advanced MalignanciesNurix Therapeutics, Inc. · Ovarian Cancer, EpithelialRecruitingNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 28, 2024ActualPhase 1NCT06691828Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948Nurix Therapeutics, Inc. · Healthy VolunteerCompletedNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2024ActualPhase 1NCT06593457A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult SubjectsNurix Therapeutics, Inc. · Healthy VolunteersCompletedNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 9, 2023ActualPhase 1NCT05107739A Study of DeTIL-0255 in Adults With Advanced MalignanciesNurix Therapeutics, Inc. · Platinum-resistant Ovarian CancerTerminatedNRIXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner